Subsequent Line Treatment Options For Hepatocellular Carcinoma With The american society of clinical oncology (asco) annual meeting took place from may 31 to june 4, 2024, featuring cutting edge research on treating hepatocellular carcinoma (hcc) in the subsequent. Finn rs, qin s, kudo m, et al. tislelizumab versus sorafenib in first line treatment of unresectable hepatocellular carcinoma: impact on health related quality of life in rationale301 population.
Biomedicines Free Full Text Pathogenesis And Current Treatment Recommendations 1 1. (durva treme) may be offered first line for patients with advanced hcc, 1. child pugh class a liver disease, and eastern cooperative oncology group performance status 0 1. where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered rst line. fi. Introduction. there were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (hcc) in 2020. in recent years, several newer systemic therapy options have shown efficacy in the first and second line settings for advanced hcc, including evidence of the effectiveness of combination therapy.1 3. Limited data are showing that patients who have been treated with atezo bev first line may even derive benefit from a ctla 4 pd [l]1 combination such as nivolumab ipilimumab in subsequent lines of therapy. 7,8 thus, we are in the unique and favorable situation that after first line therapy with atezo bev or durva treme, there are. This review explores the dynamic landscape of hepatocellular carcinoma (hcc) treatment, emphasizing on recent developments across various stages and therapeutic approaches. although curative strategies such as hepatectomy and thermal ablation are standard for early stage cases, high relapse rates drive investigations into adjuvant and perioperative treatment. adjuvant therapies face hurdles.
Figure 8 From A New Treatment Option For Intermediate Stage Limited data are showing that patients who have been treated with atezo bev first line may even derive benefit from a ctla 4 pd [l]1 combination such as nivolumab ipilimumab in subsequent lines of therapy. 7,8 thus, we are in the unique and favorable situation that after first line therapy with atezo bev or durva treme, there are. This review explores the dynamic landscape of hepatocellular carcinoma (hcc) treatment, emphasizing on recent developments across various stages and therapeutic approaches. although curative strategies such as hepatectomy and thermal ablation are standard for early stage cases, high relapse rates drive investigations into adjuvant and perioperative treatment. adjuvant therapies face hurdles. Finally, nivolumab and ipilimumab (yervoy, bristol myers squibb) combination therapy has been approved recently for second line treatment. nccn guidelines also list lenvatinib and sorafenib as single agent options in subsequent therapy, but those 2 therapies have not been studied in the second line and are not approved by the fda in this setting. First line therapy qualifying statements for recommendation 1.1. recommendation 1.1 is based on results from the imbrave150 phase iii rct6 comparison of atezo bev to sorafenib (hr for os: 0.58, 95% ci: 0.42 to 0.79, p = .0006) in child pugh class a patients. caution should be exercised when applying these results to patients with more advanced.
Comments are closed.